What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...
The issue is especially timely given provisions in the EU’s Digital Markets Act (DMA) designed to expand access to data held by large digital platforms. The...
Liz Bailey is the principal lecturer during multiple sessions during the event designed for mid-level or senior antitrust practitioners looking for more than...
CRA is a proud sponsor of the interactive two-day conference bringing together practitioners from across Europe and further afield, including private practice...